CureVac’s flop shows Biontech, Moderna made mRNA look too easy. German firm’s technology, dosing differ from Biontech, Moderna. CureVac’s vaccine disappointment shows that not every messenger-RNA project will live up to sky-high expectations for novel tech h/t Holger Zschaepitz

Our Twitter for Quick Updates: Twitter Follow Us